Compare SPDR Kensho Final Frontiers ETF (ROKT) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Kensho Final Frontiers ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? SPDR Kensho Final Frontiers ETF trades at $102.84 (market cap $176.19M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 143.4× SPDR Kensho Final Frontiers ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Kensho Final Frontiers ETF for 8 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| ROKT | RPRX | |
|---|---|---|
Market Cap | $176.19M | $25.27B |
Volume | 34,479 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $136.68 | $63.96 |
52-Week Low | $72.93 | $35.44 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
